Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo

Jian Ni, Koichi Takayama, Rie Ushijima, Naoko Inoshima, Junji Uchino, Taishi Harada, Takahiro Minami, Masafumi Takeshita, Caicun Zhou, Yoichi Nakanishi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Nuclear factor kappaB (NFκB) is a transcription factor which is importantly implicated in cancer cell growth. In a previous report, we confirmed that lung cancer cell growth was suppressed significantly by the blockade of NFκB function. In this study the combination effect of chemotherapy and inhibition of NFκB on the human lung cancer cell line, NCI-H460, in vitro and in vivo was investigated. Materials and Methods: In the in vitro experiment, 50% of cell growth inhibitory concentrations (IC 50) of chemotherapy agents were determined alone or when combined with adenovirus mediated IκBα gene transfer. Annexin-V/PI stain and caspase 3 activity measurement were used to detect the apoptosis caused by treatment. In the in vivo experiment, the tumor growth suppressive effect of combination treatment was evaluated for tumor-bearing mice. NFκB, p53 and VEGF expression in the tumors were also analyzed immunohistologically. Results: Several chemotherapy agents, including paclitaxel, showed lower IC50s when combined with AdIκBα infection in vitro. Apoptosis through activation of the caspase 3 pathway was enhanced by the combination treatment. For established NCI-H460 tumors, combined treatment significantly inhibited tumor growth. Immunohistochemical staining showed increased expression of p65 after paclitaxel treatment, while paclitaxel in combination with AdIκBα intratumoral injection eliminated this expression accompanied by the slightly reduced expression of VEGF, with stable p53 status. Conclusion: A combination of chemotherapy and IκBα could inhibit tumor growth effectively by blocking the expression of NFκB and inducing apoptosis. Moreover, it might allow reduction of the dose of chemotherapy agents and provide benefit for clinical application.

Original languageEnglish
Pages (from-to)601-608
Number of pages8
JournalAnticancer research
Volume28
Issue number2 A
Publication statusPublished - Mar 1 2008

Fingerprint

Adenoviridae
Lung Neoplasms
Pharmaceutical Preparations
Genes
Growth
Paclitaxel
Neoplasms
Combination Drug Therapy
Drug Therapy
Caspase 3
Vascular Endothelial Growth Factor A
Apoptosis Inducing Factor
Apoptosis
Therapeutics
Annexin A5
In Vitro Techniques
Inhibitory Concentration 50
Transcription Factors
Coloring Agents
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ni, J., Takayama, K., Ushijima, R., Inoshima, N., Uchino, J., Harada, T., ... Nakanishi, Y. (2008). Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo. Anticancer research, 28(2 A), 601-608.

Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo. / Ni, Jian; Takayama, Koichi; Ushijima, Rie; Inoshima, Naoko; Uchino, Junji; Harada, Taishi; Minami, Takahiro; Takeshita, Masafumi; Zhou, Caicun; Nakanishi, Yoichi.

In: Anticancer research, Vol. 28, No. 2 A, 01.03.2008, p. 601-608.

Research output: Contribution to journalArticle

Ni, J, Takayama, K, Ushijima, R, Inoshima, N, Uchino, J, Harada, T, Minami, T, Takeshita, M, Zhou, C & Nakanishi, Y 2008, 'Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo', Anticancer research, vol. 28, no. 2 A, pp. 601-608.
Ni, Jian ; Takayama, Koichi ; Ushijima, Rie ; Inoshima, Naoko ; Uchino, Junji ; Harada, Taishi ; Minami, Takahiro ; Takeshita, Masafumi ; Zhou, Caicun ; Nakanishi, Yoichi. / Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo. In: Anticancer research. 2008 ; Vol. 28, No. 2 A. pp. 601-608.
@article{0bb77047a47647198ab133654b0de086,
title = "Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo",
abstract = "Background: Nuclear factor kappaB (NFκB) is a transcription factor which is importantly implicated in cancer cell growth. In a previous report, we confirmed that lung cancer cell growth was suppressed significantly by the blockade of NFκB function. In this study the combination effect of chemotherapy and inhibition of NFκB on the human lung cancer cell line, NCI-H460, in vitro and in vivo was investigated. Materials and Methods: In the in vitro experiment, 50{\%} of cell growth inhibitory concentrations (IC 50) of chemotherapy agents were determined alone or when combined with adenovirus mediated IκBα gene transfer. Annexin-V/PI stain and caspase 3 activity measurement were used to detect the apoptosis caused by treatment. In the in vivo experiment, the tumor growth suppressive effect of combination treatment was evaluated for tumor-bearing mice. NFκB, p53 and VEGF expression in the tumors were also analyzed immunohistologically. Results: Several chemotherapy agents, including paclitaxel, showed lower IC50s when combined with AdIκBα infection in vitro. Apoptosis through activation of the caspase 3 pathway was enhanced by the combination treatment. For established NCI-H460 tumors, combined treatment significantly inhibited tumor growth. Immunohistochemical staining showed increased expression of p65 after paclitaxel treatment, while paclitaxel in combination with AdIκBα intratumoral injection eliminated this expression accompanied by the slightly reduced expression of VEGF, with stable p53 status. Conclusion: A combination of chemotherapy and IκBα could inhibit tumor growth effectively by blocking the expression of NFκB and inducing apoptosis. Moreover, it might allow reduction of the dose of chemotherapy agents and provide benefit for clinical application.",
author = "Jian Ni and Koichi Takayama and Rie Ushijima and Naoko Inoshima and Junji Uchino and Taishi Harada and Takahiro Minami and Masafumi Takeshita and Caicun Zhou and Yoichi Nakanishi",
year = "2008",
month = "3",
day = "1",
language = "English",
volume = "28",
pages = "601--608",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 A",

}

TY - JOUR

T1 - Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo

AU - Ni, Jian

AU - Takayama, Koichi

AU - Ushijima, Rie

AU - Inoshima, Naoko

AU - Uchino, Junji

AU - Harada, Taishi

AU - Minami, Takahiro

AU - Takeshita, Masafumi

AU - Zhou, Caicun

AU - Nakanishi, Yoichi

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background: Nuclear factor kappaB (NFκB) is a transcription factor which is importantly implicated in cancer cell growth. In a previous report, we confirmed that lung cancer cell growth was suppressed significantly by the blockade of NFκB function. In this study the combination effect of chemotherapy and inhibition of NFκB on the human lung cancer cell line, NCI-H460, in vitro and in vivo was investigated. Materials and Methods: In the in vitro experiment, 50% of cell growth inhibitory concentrations (IC 50) of chemotherapy agents were determined alone or when combined with adenovirus mediated IκBα gene transfer. Annexin-V/PI stain and caspase 3 activity measurement were used to detect the apoptosis caused by treatment. In the in vivo experiment, the tumor growth suppressive effect of combination treatment was evaluated for tumor-bearing mice. NFκB, p53 and VEGF expression in the tumors were also analyzed immunohistologically. Results: Several chemotherapy agents, including paclitaxel, showed lower IC50s when combined with AdIκBα infection in vitro. Apoptosis through activation of the caspase 3 pathway was enhanced by the combination treatment. For established NCI-H460 tumors, combined treatment significantly inhibited tumor growth. Immunohistochemical staining showed increased expression of p65 after paclitaxel treatment, while paclitaxel in combination with AdIκBα intratumoral injection eliminated this expression accompanied by the slightly reduced expression of VEGF, with stable p53 status. Conclusion: A combination of chemotherapy and IκBα could inhibit tumor growth effectively by blocking the expression of NFκB and inducing apoptosis. Moreover, it might allow reduction of the dose of chemotherapy agents and provide benefit for clinical application.

AB - Background: Nuclear factor kappaB (NFκB) is a transcription factor which is importantly implicated in cancer cell growth. In a previous report, we confirmed that lung cancer cell growth was suppressed significantly by the blockade of NFκB function. In this study the combination effect of chemotherapy and inhibition of NFκB on the human lung cancer cell line, NCI-H460, in vitro and in vivo was investigated. Materials and Methods: In the in vitro experiment, 50% of cell growth inhibitory concentrations (IC 50) of chemotherapy agents were determined alone or when combined with adenovirus mediated IκBα gene transfer. Annexin-V/PI stain and caspase 3 activity measurement were used to detect the apoptosis caused by treatment. In the in vivo experiment, the tumor growth suppressive effect of combination treatment was evaluated for tumor-bearing mice. NFκB, p53 and VEGF expression in the tumors were also analyzed immunohistologically. Results: Several chemotherapy agents, including paclitaxel, showed lower IC50s when combined with AdIκBα infection in vitro. Apoptosis through activation of the caspase 3 pathway was enhanced by the combination treatment. For established NCI-H460 tumors, combined treatment significantly inhibited tumor growth. Immunohistochemical staining showed increased expression of p65 after paclitaxel treatment, while paclitaxel in combination with AdIκBα intratumoral injection eliminated this expression accompanied by the slightly reduced expression of VEGF, with stable p53 status. Conclusion: A combination of chemotherapy and IκBα could inhibit tumor growth effectively by blocking the expression of NFκB and inducing apoptosis. Moreover, it might allow reduction of the dose of chemotherapy agents and provide benefit for clinical application.

UR - http://www.scopus.com/inward/record.url?scp=42549111637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549111637&partnerID=8YFLogxK

M3 - Article

C2 - 18506998

AN - SCOPUS:42549111637

VL - 28

SP - 601

EP - 608

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 A

ER -